Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Approvals/Philippines FDA/Esosky-40

Approved

STANDARD

Esosky-40

Skymap Healthcare Pvt. Ltd.🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: 89c0dbdb1d734c7e
Company: Skymap Healthcare Pvt. Ltd.
Type: Standard

Approval Details

Approval Id: 89c0dbdb1d734c7e
Drug Approval Philippines Name: Esosky-40
Product Name: Esosky-40
Registration Number: DRP-15781
Brand Name: Esosky-40
Generic Name: Esomeprazole (as sodium)
Dosage Form: Powder for Solution for Injection (IV)
Dosage Strength: 40 mg
Manufacturer: Skymap Healthcare Pvt. Ltd.
Issuance Date: 25 September 2024
Expiry Date: 25 September 2029
Pharmacologic Category: Proton Pump Inhibitor
Classification: Prescription Drug (RX)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

89c0dbdb1d734c7e

Type

Standard

Back to Philippines FDA Approvals

Esosky-40 - Philippines FDA Drug Approval Details